BR112022012917A2 - Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica - Google Patents
Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópicaInfo
- Publication number
- BR112022012917A2 BR112022012917A2 BR112022012917A BR112022012917A BR112022012917A2 BR 112022012917 A2 BR112022012917 A2 BR 112022012917A2 BR 112022012917 A BR112022012917 A BR 112022012917A BR 112022012917 A BR112022012917 A BR 112022012917A BR 112022012917 A2 BR112022012917 A2 BR 112022012917A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- topical composition
- disorder
- jak
- mucosal
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000000699 topical effect Effects 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 239000004012 Tofacitinib Substances 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 229960000556 fingolimod Drugs 0.000 abstract 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 abstract 1
- 229960001350 tofacitinib Drugs 0.000 abstract 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 abstract 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962955847P | 2019-12-31 | 2019-12-31 | |
| US202063066717P | 2020-08-17 | 2020-08-17 | |
| US202063086442P | 2020-10-01 | 2020-10-01 | |
| US202063086275P | 2020-10-01 | 2020-10-01 | |
| PCT/US2020/067612 WO2021138525A1 (en) | 2019-12-31 | 2020-12-31 | Topical composition comprising tofacitinib and fingolimod |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012917A2 true BR112022012917A2 (pt) | 2022-09-06 |
Family
ID=74285586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012917A BR112022012917A2 (pt) | 2019-12-31 | 2020-12-31 | Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230037905A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4084776A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023509441A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020417290A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022012917A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163530A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294239A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202135825A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021138525A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010302350B2 (en) | 2009-10-02 | 2015-06-18 | Journey Medical Corporation | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US12661407B2 (en) | 2010-04-08 | 2026-06-23 | Journey Medical Corporation | Compositions, gels and foams with rheology modulators and uses thereof |
| JP7324210B2 (ja) * | 2018-01-31 | 2023-08-09 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッド | トファシチニブを含む局所製剤 |
| CN116437921A (zh) * | 2020-09-28 | 2023-07-14 | 株式会社Lg化学 | 鞘氨醇-1-磷酸酯受体激动剂的用途 |
| CN120168480A (zh) * | 2025-04-17 | 2025-06-20 | 四川省医学科学院·四川省人民医院 | 托法替尼在制备治疗干性年龄相关性黄斑变性的药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4874794A (en) | 1989-04-28 | 1989-10-17 | Lidak Biopharmaceuticals | Inflammatory disease treatment |
| US9474720B2 (en) | 2013-11-04 | 2016-10-25 | BioPharmX, Inc. | Dosage form comprising an active ingredient and a plurality of solid porous microcarriers |
-
2020
- 2020-12-31 AU AU2020417290A patent/AU2020417290A1/en not_active Abandoned
- 2020-12-31 US US17/758,175 patent/US20230037905A1/en not_active Abandoned
- 2020-12-31 TW TW109147197A patent/TW202135825A/zh unknown
- 2020-12-31 WO PCT/US2020/067612 patent/WO2021138525A1/en not_active Ceased
- 2020-12-31 BR BR112022012917A patent/BR112022012917A2/pt not_active Application Discontinuation
- 2020-12-31 JP JP2022540904A patent/JP2023509441A/ja active Pending
- 2020-12-31 EP EP20845858.8A patent/EP4084776A1/en not_active Withdrawn
- 2020-12-31 CA CA3163530A patent/CA3163530A1/en active Pending
- 2020-12-31 IL IL294239A patent/IL294239A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3163530A1 (en) | 2021-07-08 |
| EP4084776A1 (en) | 2022-11-09 |
| WO2021138525A1 (en) | 2021-07-08 |
| IL294239A (en) | 2022-08-01 |
| TW202135825A (zh) | 2021-10-01 |
| AU2020417290A1 (en) | 2022-05-26 |
| US20230037905A1 (en) | 2023-02-09 |
| JP2023509441A (ja) | 2023-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001607A (es) | Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola. | |
| MX2026002469A (es) | Nuevas moleculas de acido nucleico artificiales | |
| PH12018502634A1 (en) | Topical compositions of apremilast | |
| EP4338804A3 (en) | Epinephrine spray formulations | |
| CL2023000921A1 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| CO2018005361A2 (es) | Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración | |
| BR112013026494A2 (pt) | composto, composição farmacêutica, método para tratar condição | |
| CO6670567A2 (es) | Métodos de tratamiento contra el cáncer pancreático | |
| BR112015001782A2 (pt) | método para produzir uma composição para o tratamento de um dente lesionado | |
| BR112014026058A2 (pt) | composições para tratamento tópico de infecções microbianas | |
| MX2020012018A (es) | Composiciones para el tratamiento de condiciones de la piel. | |
| BR112021021676A2 (pt) | Uso de preparação de exossomo de células-tronco mesenquimais para a preparação de composição para o tratamento da doença periodontal | |
| WO2024163641A3 (en) | Formulations for treating cancer | |
| MX382357B (es) | Métodos y composiciones para tratar infecciones fúngicas cutáneas. | |
| BR112016024621A2 (pt) | composições para tratamento bucal | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| WO2023097194A3 (en) | Bicyclic therapeutic compounds and methods of use in the treatment of cancer | |
| PH12022552738A1 (en) | Compositions comprising nanoparticles, method of making and uses thereof | |
| EP4357334A3 (en) | Conjugated oligonucleotide compounds, methods of making and uses thereof | |
| MX2024005303A (es) | Formulaciones biotensioactivas para su uso en el cuidado de la piel y el tratamiento de heridas. | |
| WO2024006292A3 (en) | Methods of treating cancer | |
| BR112022003659A2 (pt) | Composições e métodos de tratamento de doenças vasculares | |
| MX2019011933A (es) | Composiciones cosmeticas que contienen sistema enzimatico. | |
| BR112022018770A2 (pt) | Composição alogênica compreendendo células t vd1+, dose, e, método de tratamento de uma malignidade mieloide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |